Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content
Cancer PHGKB

Specific PHGKB|Cancer|Public Health Genomics and Precision Health Knowledge Base (PHGKB)
Effective August 1, 2024, this database will be discontinued. All content will remain searchable and be preserved online for historical purposes only until 2029.

Last Posted: Jul 22, 2024
spot light Spotlight

Advancing Genomic Cancer Medicine in Rural and Underserved States
(Posted Jul 22, 2024 10AM)

From the article: "In the evolving landscape of oncology, the integration of powerful genomic technologies into practice has ushered in a new era of precision cancer medicine. Complex genomic information such as mutational analyses, transcriptional signatures, and polygenic risk scores have become key diagnostics guiding therapeutic decisions and management of inherited cancer risk. However, the expertise to interpret these data for clinical decision-making remains constrained and is a significant challenge for community oncologists, especially those in rural regions and in medically underserved areas. While physical access to these tests is readily available, poor access to interpretive expertise has become the key limiting factor. "

Benefits for children with suspected cancer from routine whole-genome sequencing
(Posted Jul 18, 2024 8AM)

From the abstract: " Clinical whole-genome sequencing (WGS) has been shown to deliver potential benefits to children with cancer and to alter treatment in high-risk patient groups. It remains unknown whether offering WGS to every child with suspected cancer can change patient management. We collected WGS variant calls and clinical and diagnostic information from 281 children (282 tumors) across two English units (n=152 from a hematology center, n?=?130 from a solid tumor center) where WGS had become a routine test. Our key finding was that variants uniquely attributable to WGS changed the management in ~7% (20 out of 282) of cases while providing additional disease-relevant findings, beyond standard-of-care molecular tests, in 108 instances for 83 (29%) cases."

A roadmap for affordable genetic medicines
(Posted Jul 18, 2024 8AM)

From the abstract: "Nineteen genetic therapies have been approved by the U.S. Food and Drug Administration (FDA) to date, a number that now includes the first CRISPR genome editing therapy for sickle cell disease, CASGEVY (exagamglogene autotemcel). This extraordinary milestone is widely celebrated because of the promise for future genome editing treatments of previously intractable genetic disorders and cancers. At the same time, such genetic therapies are the most expensive drugs on the market, with list prices exceeding $4 million per patient. "

BRCA1 and friends 30 years on
(Posted Jul 08, 2024 8AM)

From the abstract: "With the benefit of hindsight, recognition of the cancer susceptibility gene BRCA1 and its later cloning were defining moments for breast and ovarian cancer genetics that should be celebrated. "

news Latest News and Publications
Identifying risk factors for severe omicron infection in allogeneic hematopoietic stem cell transplant recipients with hematologic malignancies. External Web Site Icon
Li Zhihui, et al. Cancer reports (Hoboken, N.J.) 2024 0 0. (6) e2103
Report of the sixth meeting of the European Consortium 'Care for CMMRD' (CCMMRD), Paris, France, November 16th 2022. External Web Site Icon
Guerrini-Rousseau Léa, et al. Familial cancer 2024 0 0.
Assessing the Relationship Between Neighborhood Socioeconomic Disadvantage and Telemedicine Use Among Patients With Breast Cancer and Examining Differential Provisions of Oncology Services Between Telehealth and In-Person Visits: Quantitative Study. External Web Site Icon
Freeman Jincong Q, et al. JMIR cancer 2024 0 0. e55438
Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trial. External Web Site Icon
Griffin David W J, et al. Trials 2024 0 0. (1) 485
Deep IDA: a deep learning approach for integrative discriminant analysis of multi-omics data with feature ranking-an application to COVID-19. External Web Site Icon
Wang Jiuzhou, et al. Bioinformatics advances 2024 0 0. (1) vbae060
Household income unequally affects genetic susceptibility to pulmonary diseases: evidence from bidirectional Mendelian randomization study. External Web Site Icon
Xu Hongfa, et al. Frontiers in medicine 2024 0 0. 1279697
Imaging of Biliary Tree Abnormalities. External Web Site Icon
Lopes Vendrami Camila, et al. Radiographics : a review publication of the Radiological Society of North America, Inc 2024 0 0. (8) e230174
M1-polarized macrophage-derived cellular nanovesicle-coated lipid nanoparticles for enhanced cancer treatment through hybridization of gene therapy and cancer immunotherapy. External Web Site Icon
Shin Ha Eun, et al. Acta pharmaceutica Sinica. B 2024 0 0. (7) 3169-3183
At-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methods. External Web Site Icon
Mesinovic Munib, et al. Scientific reports 2024 0 0. (1) 16387
Identification of risk factors of Long COVID and predictive modeling in the RECOVER EHR cohorts. External Web Site Icon
Zang Chengxi, et al. Communications medicine 2024 0 0. (1) 130
Cancer predisposing syndromes in childhood and adolescence pose several challenges necessitating interdisciplinary care in dedicated programs. External Web Site Icon
Stefanie Kaffai et al. Front Pediatr 2024 121410061
Comparative Evaluation of Machine Learning Models for Subtyping Triple-Negative Breast Cancer: A Deep Learning-Based Multi-Omics Data Integration Approach. External Web Site Icon
Shufang Yang et al. J Cancer 2024 15(12) 3943-3957
Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US. External Web Site Icon
Junjie Pan et al. Sci Rep 2024 14(1) 13935
Effectiveness of colorectal cancer screening integrating non-genetic and genetic risk: a prospective study based on UK Biobank data. External Web Site Icon
Yu Zhang et al. Cancer Biol Med 2024
Genomic Newborn Screening for Pediatric Cancer Predisposition Syndromes: A Holistic Approach. External Web Site Icon
BalaSubramani Gattu Linga et al. Cancers (Basel) 2024 16(11)
Healthcare Professionals' Learning Needs and Perspectives on Essential Information in Genetic Cancer Care: A Systematic Review. External Web Site Icon
Sun-Young Park et al. Cancers (Basel) 2024 16(11)
Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer. External Web Site Icon
Claudia Rosso et al. J Natl Compr Canc Netw 2024 1-7
Risk-reducing salpingo-oophorectomy among diverse patients with BRCA mutations at an urban public hospital: a mixed methods study. External Web Site Icon
Alexandra J Lamacki et al. BMJ Open 2024 14(6) e082608
Screening guidelines for people at increased risk for prostate cancer. External Web Site Icon
Justin Lorentz et al. Can Urol Assoc J 2024
Deep Learning Analysis for Predicting Tumor Spread through Air Space in Early-Stage Lung Adenocarcinoma Pathology Images. External Web Site Icon
De-Xiang Ou et al. Cancers (Basel) 2024 16(11)


Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.